BioSpace News Archive

Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict Progression to AD Early in the Disease Process with >90% Accuracy

Shenzhen Pregene Biopharma and Dr. Reddy’s Laboratories announce a license agreement whereby Dr Reddy’s will acquire the exclusive rights in the Republic of India for PRG1801, an anti-BCMA CAR-T cell therapy injection based on single domain antibody technology, from Shenzhen Pregene Biopharma.

NAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program Presented at ATS 2021 International Conference

Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, announces the strengthening of its Board and Management as well as a pre-IPO funding round to advance its lead novel hybrid interferon drug candidate Alfacyte™.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the first quarter ended March 31, 2021 and provided a business update.

Meditrial Inc, a leading Global Digitally Driven Research Organization, is pleased to announce its successful collaboration with CrannMed Limited in supporting their objective to obtain a Breakthrough Device Designation by the U.S Food and Drug Administration for its Embosure Microspheres used to treat patients suffering from pain associated with Knee Osteoarthritis.

Immuron Limited is pleased to provide shareholders and the market with an update on the anti-viral activity of IMM124E used to manufacture the company’s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn®.

BD, a leading global medical technology company, announced the industry’s first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.

Second Sight Medical Products, Inc., a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that the Company received notice from the National Institutes of Health of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442.